We are live on ! Find out more
MWNA

Marshall Wace North America Portfolio holdings

AUM $23.5B
1-Year Est. Return 46.46%
This Fund
S&P 500
This Quarter Est. Return
+5.07%
1 Year Est. Return
+46.46%
3 Year Est. Return
+109.4%
5 Year Est. Return
10 Year Est. Return
AUM
$15.8B
AUM Growth
+$2.12B
Cap. Flow
+$1.31B
Cap. Flow %
8.29%
Top 10 Hldgs %
13.54%
Holding
1,739
New
469
Increased
384
Reduced
350
Closed
529

Sector Composition

Rank Sector Weight
1 Healthcare 19.65%
2 Technology 16.89%
3 Consumer Discretionary 13.55%
4 Industrials 12.67%
5 Financials 6.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SKM icon
626
SK Telecom
SKM
$13.2B
$3.79M 0.02%
91,958
+71,343
+346% +$3.01M
FOMX
627
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.77M 0.02%
628,244
-4,575
-0.7% -$23.6K
NVMI
628
Nova
NVMI
$12.3B
$3.76M 0.02%
+134,362
New +$3.27M
TDOC icon
629
Teladoc Health
TDOC
$1.29B
$3.75M 0.02%
+113,562
New +$3.72M
UTHR icon
630
United Therapeutics
UTHR
$22.8B
$3.74M 0.02%
+31,964
New +$4.08M
TTEK icon
631
Tetra Tech
TTEK
$9.05B
$3.71M 0.02%
394,500
+344,690
+692% +$3.03M
SHOO icon
632
Steven Madden
SHOO
$3.54B
$3.69M 0.02%
128,690
+117,720
+1,073% +$3.24M
HAE icon
633
Haemonetics
HAE
$3.94B
$3.68M 0.02%
+81,869
New +$3.4M
AMGN icon
634
Amgen
AMGN
$220B
$3.65M 0.02%
+19,625
New +$3.48M
KWR icon
635
Quaker Houghton
KWR
$2.95B
$3.65M 0.02%
+24,648
New +$3.51M
RGEN icon
636
Repligen
RGEN
$9.19B
$3.64M 0.02%
95,906
-318,240
-77% -$13.3M
CBPX
637
DELISTED
CONTINENTAL BUILDING PRODUCTS, INC.
CBPX
$3.63M 0.02%
139,467
+84,128
+152% +$1.94M
PGR icon
638
Progressive
PGR
$125B
$3.6M 0.02%
75,012
-164,285
-69% -$7.68M
LULU icon
639
lululemon athletica
LULU
$14.5B
$3.59M 0.02%
57,962
-405,527
-87% -$24.4M
KYNB
640
Kyntra Bio
KYNB
$29.1M
$3.59M 0.02%
+2,659
New +$2.8M
OEC icon
641
Orion
OEC
$409M
$3.58M 0.02%
162,807
+93,429
+135% +$2M
TVTY
642
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$3.58M 0.02%
+87,258
New +$3.38M
CBT icon
643
Cabot Corp
CBT
$4.49B
$3.57M 0.02%
63,819
+23,326
+58% +$1.25M
FCX icon
644
Freeport-McMoran
FCX
$97.3B
$3.55M 0.02%
+253,767
New +$3.56M
BUFF
645
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
$3.54M 0.02%
126,293
-868,816
-87% -$21.3M
SAGE
646
DELISTED
Sage Therapeutics
SAGE
$3.53M 0.02%
56,961
-285,277
-83% -$22.4M
REN
647
DELISTED
Resolute Energy Corporaton
REN
$3.48M 0.02%
+116,138
New +$3.45M
HSTM icon
648
HealthStream
HSTM
$844M
$3.48M 0.02%
+151,177
New +$3.59M
CAKE icon
649
Cheesecake Factory
CAKE
$5.33B
$3.48M 0.02%
82,757
-310,461
-79% -$13.8M
BKD icon
650
Brookdale Senior Living
BKD
$3.42B
$3.47M 0.02%
315,466
+304,864
+2,876% +$3.86M

Similar funds

Marshall Wace North America's Q3 2017 Portfolio in Review

As of Q3 2017, Marshall Wace North America held 1,739 positions worth $15.8B, up 16% from $13.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Marshall Wace North America deployed $1.31B of net new capital in Q3 2017, opening 469 new positions and adding to 384 existing holdings. Its largest new stake was Delta Air Lines: 1,523,510 shares worth $73.1M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Terminix Global Holdings, Inc., an estimated $113M trimmed.

  • Marshall Wace North America's largest Q3 2017 buy was Delta Air Lines: 1,523,510 shares worth $73.1M.
  • Marshall Wace North America added most to Johnson & Johnson in Q3 2017, an estimated $260M increase.
  • Marshall Wace North America's biggest Q3 2017 reduction was Terminix Global Holdings, Inc., cutting an estimated $113M.
  • Marshall Wace North America fully exited Reynolds American Inc in Q3 2017, selling an estimated $130M.
  • Marshall Wace North America's ten largest holdings make up 14% of its $15.8B portfolio in Q3 2017.
  • Marshall Wace North America opened 469 new positions and closed 529 in Q3 2017.
  • Marshall Wace North America's portfolio value rose 16% quarter-over-quarter to $15.8B.

Based on Marshall Wace North America's 13F filing for Q3 2017, filed 13 Nov 2017.